Studies: Bristol-Myers hepatitis drug bests GSK's

03/8/2006 | AlertNet

The results of two studies of long-term liver disease indicate Bristol-Myers Squibb's entecavir is more effective in treating hepatitis B than GlaxoSmithKline's Epivir. The studies in the New England Journal of Medicine, funded by Bristol-Myers, also said entecavir has a low rate of antiviral resistance.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC